Genmab A/S
DUS:GE9
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
Genmab A/S
DUS:GE9
|
DK |
Intrinsic Value
The intrinsic value of 
Genmab A/S (GE9) under the Base Case is 341.72 EUR per share.
Compared with the current market price of 473.4 EUR, the stock appears
Overvalued by 28% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Genmab A/S Does
Genmab A/S is a biotechnology company that discovers and develops antibody medicines for cancer and other serious diseases. It does not make broad consumer products; instead, it focuses on turning lab-made antibodies into drug candidates that can be tested, approved, and sold by itself or with larger drugmakers.
- Headquarters
- Denmark DK
- Employees
- 3 088
- IPO date
- Oct 1, 2000
Genmab A/S has a narrow economic moat
Patents on Genmab’s antibody medicines and technologies make it harder for rivals to copy protected treatments, while partner sales allow Genmab to earn royalties from some of them. This protection supports its position in markets where approved medicines compete for patients.
Read the full moat analysis
Revenue & Expenses Breakdown
Genmab A/S
Earnings Waterfall
Genmab A/S
The intrinsic value for Genmab A/S (GE9) under the Base Case is 341.72 EUR.
Compared with the current market price of 473.4 EUR, the stock appears Overvalued by 28% .
